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Abstract The rabbit lens has an elevated content of 3-
hydroxykynurenine (3OHKYN) in spite of a very low activity
of the enzymes leading to its synthesis. The iris/ciliary body, on
the contrary, has very high activity of 3OHKYN synthesizing
enzymes but a content of 3OHKYN lower than that of the lens.
These observations suggest that 3OHKYN is formed in the iris/
ciliary body, released into the aqueous humor and then taken up
into the lens where it may be used for the synthesis of UV
filtering products. An excessive accumulation of 3OHKYN in the
lens has been associated with cataract formation. We found that
available selective inhibitors of kynurenine hydroxylase reduced
3OHKYN synthesis in both the lens and the iris/ciliary body.
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1. Introduction
It has been proposed that 3-hydroxykynurenine (3OH-
KYN), a tryptophan (TRP) metabolite formed along the
‘kynurenine metabolic pathway’, may play a role in visual
function because it is present in elevated concentrations in
the lens and is able to absorb UV radiation [1]. Indeed,
3OHKYN itself, its glucoside derivative and the glucoside
derivatives of 4-(2-amino-3-hydroxyphenyl)-4-oxobutanoic
acid, one of the numerous 3OHKYN metabolites, are e¡ective
¢lters of sunlight and their presence in the lens of diurnal
animals may be useful in protecting the retina from UV radi-
ation [2^4]. However, a key role for 3OHKYN and its metab-
olites has also been proposed in the processes leading to lens
opaci¢cation and senile cataract formation because they may
undergo complex autoxidative processes which may lead to
the formation of radical species able to react with crystallins
[5^9]. The localization and properties of the enzymes of the
kynurenine pathway which catalyze the reactions leading from
TRP to pyridine nucleotides (NAD and NADP) have been
widely studied in the past several years (see [10,11] for re-
views) and it has also been shown that lens epithelial cells
synthesize 3OHKYN when incubated with labeled TRP [3].
However, quantitative studies aimed at understanding the rate
of 3OHKYN synthesis and catabolism in di¡erent eye struc-
tures are not available. In this study we measured the content
of 3OHKYN and related metabolites together with the activ-
ity of the kynurenine pathway enzymes in di¡erent tissues of
the rabbit eye, in order to study their role in visual function.
The results we obtained showed that the enzymes leading to
3OHKYN synthesis are mostly present in the iris/ciliary body
while the lens, in spite of an elevated content of this com-
pound, has a very low activity of the enzymes responsible
for its synthesis.
Several selective inhibitors of kynurenine hydroxylase (EC
1.14.13.9) (KH), the key enzyme in the synthesis of 3OH-
KYN, have previously been described utilizing brain or liver
enzymatic preparations [12^15]. We report here that these
inhibitors are also e¡ective in the iris/ciliary body and the
lens and therefore seem useful tools to study the role of 3OH-
KYN in the eye.
2. Materials and methods
2.1. Materials
(m-Nitrobenzoyl)-alanine (mNBA), 3,4-dimethoxy-[N-4-(3-nitro-
phenyl) thiazol-2-yl]-benzenesulfonamide (Ro 61-8048) [15] and
L-[3-3H]kynurenine (speci¢c activity 14.4^16.1 Ci/mmol; 1 Ci = 37
GBq) were kindly provided by Drs. S. Roever and A. Cesura (Ho¡-
man-La Roche, Basel, Switzerland). [137 C]QUIN was provided by Dr.
J.F. Reinhard Jr. (Glaxo-Wellcome, Research Triangle Park, NC,
USA). Kynurenine (KYN), kynurenic acid (KYNA), anthranilic
acid (ANA), 3-hydroxyanthranilic acid (3OHANA), 3OHKYN,
xanthurenic acid (XANT) and quinolinic acid (QUIN) were from
Sigma (St. Louis, MO, USA). Hexa£uor-2-propanol and tri£uoro-
acetyl-imidazole were from Aldrich (Milan, Italy). All remaining com-
pounds were from Merck (Darmstadt, Germany).
2.2. Tissue preparation
Tissues were obtained from male New Zealand rabbits (2.5^3 kg)
killed with an i.v. injection of 100 mg sodium thiopental. The eyes
were rapidly collected, the cornea was removed and the bulbs dis-
sected into iris/ciliary body, lens, vitreous and humor aqueous. A
portion of the liver, lung and blood of each animal was also collected
and all tissues were stored at 380‡C until processed. 0.5 g of each
tissue was homogenized with an equal volume of 20% trichloroacetic
acid and centrifuged at 14 000 rpm for 10 min. Aliquots of super-
natants were injected in the HPLC apparatus for measurements of
the contents of KYN, 3OHKYN, ANA, 3OHANA, XANT and
KYNA. A portion of the supernatant was extracted with chloroform
for QUIN measurement (see below). Another portion of each tissue
was homogenized in eight volumes (w/v) of ice-cold 0.1 M potassium
phosphate bu¡er pH 8 containing EDTA (1 mM), dithiothreitol
(1 mM), leupeptin (2 Wg/ml), aprotinin (2 Wg/ml) and phenylmethyl-
sulfonyl £uoride (100 Wg/ml) for the evaluation of the enzymatic ac-
tivities. The homogenates were centrifuged at 15 000 rpm for 10 min
to obtain a crude preparation of mitochondria which was re-sus-
pended in 8 volumes (w/v) of the homogenization bu¡er.
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2.3. Evaluation of enzyme activities
Indoleamine 2,3-dioxygenase (IDO) (EC 1.13.11.42) activity was
evaluated according to Takikawa et al. [16]. The reaction mixture
consisted of 50 Wl of the cytosol preparation of tissue homogenates
and 50 Wl of 0.1 M phosphate bu¡er pH 6.5 containing 20 mM
ascorbate, 50 WM methylene blue, 200 Wg catalase and 2 mM TRP.
After 30 min incubation at 37‡C, the reaction was terminated with
100 Wl of 20% (w/v) trichloroacetic acid, and the mixtures centrifuged
at 14 000 rpm for 5 min. Aliquots of the supernatants were injected
into the HPLC apparatus for measurements of KYN synthesis.
KH activity was evaluated in some experiments by monitoring the
synthesis of 3OHKYN using HPLC and electrochemical detection [12]
and in other experiments by using the radiometric method described
by Erickson et al. [17]. In the ¢rst approach the reaction mixture was:
50 Wl of crude mitochondria preparation and 50 Wl of 0.1 M phos-
phate bu¡er pH 8 containing NADPH 8 mM and KYN 2 mM. After
30 min incubation at 37‡C, the reaction was terminated with 100 Wl of
20% (w/v) trichloroacetic acid, and the samples centrifuged at 14 000
rpm for 5 min. Aliquots of the supernatant were injected into the
HPLC apparatus. In the second approach, 0.2 WCi of L-[3-3H]KYN
was added to the reaction mixture. In this case the reaction was
terminated by the addition of 500 Wl of a 5% suspension of activated
charcoal (Norit A) and after shaking for 1 min, the samples were
centrifuged at 14 000 rpm for 10 min. 250 Wl of the supernatants
were added to vials containing 4 ml of scintillation £uid (Insta-Gel
Plus, Packard) for the measurement of radioactivity. These methods
gave similar results, and the use of radioactivity was preferred for
tissues with low KH activity.
The activity of the enzyme able to cleave 3OHKYN and KYN
(kynureninase, KASE) (EC 3.7.1.3) was evaluated by measuring the
formation of ANA. The enzymatic mixture consisted of 50 Wl of the
cytosol preparation and 50 Wl of 0.1 M phosphate bu¡er pH 8 con-
taining 200 WM pyridoxal phosphate and 2 mM KYN. After 30 min
of incubation at 37‡C, the reaction was terminated with 100 Wl of 20%
(w/v) trichloroacetic acid, and the samples centrifuged at 14 000 rpm
for 5 min. Aliquots of the supernatant were injected in the HPLC
apparatus for ANA quantitation (see below).
Kynurenine aminotransferase (KAT) is the second enzyme able to
metabolize KYN and 3OHKYN with the synthesis of KYNA and
XANT, respectively. This activity was evaluated by measuring
XANT formation. The reaction mixture consisted of: 50 Wl cytosol
preparation, 50 Wl 0.1 M phosphate bu¡er pH 8, 200 WM pyridoxal
phosphate, 20 mM K-ketoglutaric acid and 2 mM 3OHKYN. After 30
min incubation at 37‡C, the reaction was terminated with 100 Wl of
20% (w/v) trichloroacetic acid. The samples were centrifuged at 14 000
rpm for 5 min and aliquots of the supernatant were injected in the
HPLC apparatus for the measurement of XANT (see below).
2.4. Measurements of KYN, KYNA and XANT
KYN, KYNA and XANT were measured using HPLC and UV
detection as described by Holmes [18]. Brie£y, a reverse phase column
(Spherisorb S5 ODS2, 10 cm) and a mobile phase containing 0.1 mM
ammonium acetate, 0.1 M acetic acid and 2% acetonitrile, 1 ml/min
£ow rate were used. KYN was detected at 365 nm while KYNA and
XANT were detected at 338 nm (UV detector: Perkin Elmer model
LC 90).
2.5. Measurements of ANA and 3OHANA
ANA and 3OHANA were measured using HPLC and £uorimetric
detection as previously described [14]. Separation was obtained using
a reverse phase column (S5 ODS2, 15 cm) and a mobile phase (£ow
rate of 0.8 ml/min) composed of 20 mM sodium acetate bu¡er pH 4.5
and 5% methanol. Detection was obtained with a Perkin Elmer model
LC 240 £uorimeter: excitation and emission wavelengths were 313
and 420 nm respectively.
2.6. Measurements of 3OHKYN
3OHKYN was measured using HPLC and electrochemical detec-
tion [19]. Separation was obtained with a reverse phase column
(Spherisorb S5 ODS2, 25 cm) and a mobile phase (£ow rate 1.5 ml/
min) composed of 2% acetonitrile, 0.9% triethylamine, 0.59% phos-
phoric acid, 9 mM heptane sulfonic acid and 0.25 mM sodium EDTA.
Detection was obtained with a coulometric detector (ESA model 5100
A) operating at a preoxidation voltage of 0.03 V and an oxidation
voltage of 0.23 V.
2.7. Measurements of QUIN
QUIN was measured using GC/MS and a modi¢cation of proce-
dures previously reported [20,21]. Brie£y, after the addition of
[137 C]quinolinate as an internal standard, each sample was dried and
derivatized at 80‡C for 1 h with 100 Wl of hexa£uoro-2-propanol and
100 Wl of tri£uoroacetyl-imidazole. 100 Wl of water and 100 Wl of
heptane were added to the derivatized samples which were vigorously
mixed and then frozen at 380‡C. The heptane fraction was collected
and injected into a GC/MS system (HP 6890/5973 MSD,
HP5973MSD) equipped with an automatic injector. The chromato-
graphic column used was a HP 5MS 30 mU0.25 mmU0.25 Wm. The
carrier gas was helium at a constant £ow of 1.2 ml/min. The oven
temperature was: 1 min at 80‡C, raised at a rate of 10‡C/min to 135‡C
and then at a rate of 25‡C/min to 300‡C. Injector and transfer line
temperatures were 230‡C and 270‡C respectively. The mass spectrom-
etry detector operated in negative ion chemical ionization mode using
methane as a negative gas. The recorded ions were m/z 467 for qui-
nolinate and m/z 474 for [137 C]quinolinate. The dwell time was 70 ms
for each ion.
2.8. Protein determination
Protein content was determined by the Pierce bicinchoninic acid
assay kit according to the manufacturer’s instructions.
3. Results
3.1. Content and distribution of the ‘kynurenines’ in the eye
Table 1 reports the content of the ‘kynurenines’ in the iris/
ciliary body, lens, aqueous humor, vitreous and blood. The
concentration of 3OHKYN in the lens was seven times higher
and in the iris/ciliary body two times higher than in the blood.
The concentration of XANT, a direct 3OHKYN metabolite,
was also signi¢cantly higher in the lens and in the iris/ciliary
body than in the blood. The concentration of 3OHANA,
Fig. 1. Inhibition of iris/ciliary body (A) and lens (B) kynurenine hydroxylase activity by Ro 61-8048 (¢lled circles) and mNBA (open circles).
The concentration of KYN used was 100 WM (see Section 2). Each point is the mean þ S.E.M. of three experiments conducted in duplicate.
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another 3OHKYN metabolite, was, on the contrary, three
times lower in the lens and iris/ciliary body than in the blood.
3.2. Distribution of the kynurenine pathway enzymes in the eye
In order to study why the iris/ciliary body and lens had
3OHKYN concentrations higher than the blood, we measured
in these eye structures the activity of the following enzymes:
IDO, KH, KASE and KAT, which are involved in the syn-
thesis and catabolism of 3OHKYN. Table 2 shows that IDO
activity was particularly elevated in the iris/ciliary body where
it reached a level similar to that found in the lung, an organ
with very high enzymatic activity [22]. KH activity was also
notably elevated in the iris/ciliary body where it reached a
level 10-fold higher than that observed in the liver, an organ
particularly rich in this enzyme [23] (Table 2). The enzymatic
activities responsible for 3OHKYN catabolism (namely,
KASE and KAT) were several times lower in the iris/ciliary
body than in the liver (Table 2). Unexpectedly, the activity of
the enzymes responsible for 3OHKYN formation was quite
low in the lens, a structure having a high 3OHKYN content
(see Tables 1 and 2).
3.3. E¡ects of Ro 61-8048 and mNBA.
Ro 61-8048 and mNBA inhibited KH activity in the iris/
ciliary body with IC50s of 0.1 þ 0.06 and 1.3 þ 0.2 WM, respec-
tively (Fig. 1A). In the lens, the IC50 was 1 þ 0.2 for Ro 61-
8048 and 7 þ 2 WM for mNBA (Fig. 1B).
4. Discussion
The present data show that: (1) the iris/ciliary body has a
very high level of 3OHKYN-forming and a low level of 3OH-
KYN-catabolizing enzyme activities; (2) the lens contains ele-
vated 3OHKYN concentrations in spite of low activities of
3OHKYN-forming enzymes (see Tables 1 and 2). It is there-
fore reasonable to propose that 3OHKYN is mostly formed in
the iris/ciliary body, released into the aqueous humor and
then taken up into the lens where it may be used for the
synthesis of UV-¢ltering compounds. In support of this hy-
pothesis is the demonstration that 3OHKYN is more concen-
trated in the anterior portion of the lens [3] and that the lens
epithelial cells express the neutral amino acid carrier which is
able to take up KYN and 3OHKYN [24^26]. An excessive
accumulation of 3OHKYN or of its metabolites, however,
may participate in the processes leading to the formation of
free radical species which are responsible for a number of
tissue injuries [27,28] including lens opaci¢cation and cataract
formation [9,29,30]. In this respect XANT seems particularly
important, as it is present in the lens at a concentration ap-
proximately four times that of the blood (see Table 1) and it
may be metabolized into oxo- and dioxo-XANT, both of
which have been involved in the cataractogenic process
[31,32]. Another 3OHKYN metabolite previously studied in
the process of cataract formation is 3OHANA, which may
easily undergo autoxidation and be responsible for the syn-
thesis of reactive compounds (cinnabarinic acid and p-quinone
dimer) which seem to participate in the process of lens opac-
i¢cation [7]. However, in the lens, the activity of the 3OHA-
NA-forming enzyme (KASE) is relatively low (Table 2) and
3OHANA content is signi¢cantly lower than in blood (Table
1). These observations tend to rule out the possibility that
3OHANA has a basic role in cataract formation processes.
Our proposal that the iris/ciliary body releases 3OHKYN into
the aqueous humor could explain the elevated content of this
compound in the lens. However, we cannot completely rule
out the possibility that the low activity of 3OHKYN-forming
enzymes in the whole lens is the result of a high activity in the
epithelium diluted by the protein of the whole lens.
The extremely elevated activity of 3OHKYN-forming en-
zymes in the iris/ciliary body may suggest that 3OHKYN
plays other important roles in this eye structure. In insects,
these enzymes are involved in the synthesis of eye pigments
[33] and it is reasonable to extend these observations to mam-
mals.
We have previously studied the pharmacological e¡ects of
Ro 61-8048 and mNBA, two KH inhibitors [12,13,34], and
the present studies show that these compounds are not only
active in the liver and the brain, but also in the iris/ciliary
body and lens (Fig. 1). Di¡erences in IC50 values can prob-
ably be explained by unspeci¢c binding to proteins. It can
therefore be proposed that the above mentioned KH inhibi-
tors may be useful tools for reducing 3OHKYN content in the
eye and for studying the role of this TRP metabolite in eye
physiology and pathology.
Table 1
Contents of the ‘kynurenines’ in rabbit blood and eye structures
KYN KYNA ANA 3OHKYN XANT 3OHANA QUIN
Iris/ciliary body 6.7 þ 0.43 0.9 þ 0.5 0.12 þ 0.01 1.85 þ 0.5* 1.72 þ 0.4* 0.04 þ 0.01* 1.04 þ 0.4**
Aqueous humor 1 þ 0.2** 0.16 þ 0.03* 0.02 þ 0.01* 0.6 þ 0.2 0.04 þ 0.01 0.05 þ 0.01* 0.16 þ 0.05
Lens 2.4 þ 0.2* 0.02 þ 0.01** 0.08 þ 0.03 5 þ 1.3** 0.25 þ 0.06* 0.06 þ 0.01* 0.02 þ 0.01*
Vitreous 0.46 þ 0.11** 0.02 þ 0.01** 0.2 þ 0.1* 0.14 þ 0.05* 0.05 þ 0.01 0.05 þ 0.02* 0.02 þ 0.01*
Blood 7.3 þ 1.8 0.64 þ 0.3 0.11 þ 0.01 0.73 þ 0.16 0.07 þ 0.02 0.19 þ 0.05 0.22 þ 0.08
Values are nmol/g or nmol/ml (mean þ S.E.M. of at least ¢ve samples). *P6 0.05; **P6 0.01 vs. blood, ANOVA and Tukey t-test.
Table 2
IDO, KH, KASE and KAT activity in rabbit iris/ciliary body, lens, liver and lung
IDO KH KASE KAT
Iris/ciliary body 326 þ 44 130 þ 20 0.46 þ 0.17 5.8 þ 0.6
Lens 8 þ 1.2 2.3 þ 0.7 0.13 þ 0.02 0.06 þ 0.01
Liver 62.5 þ 11 17.2 þ 5 247 þ 7 82.5 þ 12
Lung 425 þ 53 1.15 þ 0.4 4.4 þ 0.6 2.32 þ 0.7
Values are pmol/mg protein/min (mean þ S.E.M. of ¢ve experiments).
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